Cogent Biosciences/$COGT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cogent Biosciences
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Ticker
$COGT
Sector
Primary listing
Employees
205
Headquarters
Website
COGT Metrics
BasicAdvanced
$2.2B
-
-$2.52
0.36
-
Price and volume
Market cap
$2.2B
Beta
0.36
52-week high
$17.15
52-week low
$3.72
Average daily volume
2.3M
Financial strength
Current ratio
4.194
Quick ratio
4.071
Long term debt to equity
38.056
Total debt to equity
39.125
Interest coverage (TTM)
-954.34%
Profitability
EBITDA (TTM)
-297.123
Management effectiveness
Return on assets (TTM)
-53.15%
Return on equity (TTM)
-107.55%
Valuation
Price to book
38.71
Price to tangible book (TTM)
38.71
Price to free cash flow (TTM)
-7.685
Free cash flow yield (TTM)
-13.01%
Free cash flow per share (TTM)
-2.082
Growth
Earnings per share change (TTM)
1.99%
3-year earnings per share growth (CAGR)
0.43%
What the Analysts think about COGT
Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.
Bulls say / Bears say
In July 2025, Cogent's SUMMIT trial showed bezuclastinib delivered an 8.91-point placebo-adjusted reduction in symptom score at 24 weeks and 87.4% of patients achieved ≥50% serum tryptase reduction, meeting all primary and key secondary endpoints (Investing.com)
Cogent secured a $400 million non-dilutive debt facility with SLR Capital Partners in June 2025, with $50 million drawn at closing and additional tranches tied to key clinical and commercial milestones, bolstering its financial runway into 2026 (BioSpace)
On July 18, 2025, Citi increased its price target for COGT to $22, citing strong SUMMIT data and projecting up to 52% upside, reflecting growing analyst confidence in bezuclastinib’s commercial potential (Investing.com)
Cogent reported a Q2 2025 net loss of $73.5 million, up from $59.0 million year-over-year, primarily driven by increased R&D expenses, highlighting significant cash burn ahead of commercialization (GuruFocus)
The company’s reliance on milestone-based debt financing underscores cash dependency on successful trial outcomes, with only $50 million drawn from its $400 million facility to date and future tranches contingent on SUMMIT and PEAK readouts (BioSpace)
Cogent raised $150 million through an underwritten stock offering in July 2025, potentially diluting existing shareholders ahead of any revenue generation from bezuclastinib (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
COGT Financial Performance
Revenues and expenses
COGT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cogent Biosciences stock?
Cogent Biosciences (COGT) has a market cap of $2.2B as of October 30, 2025.
What is the P/E ratio for Cogent Biosciences stock?
The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of October 30, 2025.
Does Cogent Biosciences stock pay dividends?
No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Cogent Biosciences dividend payment date?
Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Cogent Biosciences?
Cogent Biosciences (COGT) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.